CO6541585A2 - Composiciones de lipopétidos y métodos relacionados - Google Patents

Composiciones de lipopétidos y métodos relacionados

Info

Publication number
CO6541585A2
CO6541585A2 CO12097444A CO12097444A CO6541585A2 CO 6541585 A2 CO6541585 A2 CO 6541585A2 CO 12097444 A CO12097444 A CO 12097444A CO 12097444 A CO12097444 A CO 12097444A CO 6541585 A2 CO6541585 A2 CO 6541585A2
Authority
CO
Colombia
Prior art keywords
compositions
lipopeptides
related methods
daptomycin
sucrose
Prior art date
Application number
CO12097444A
Other languages
English (en)
Inventor
Sophie Sun
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6541585(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of CO6541585A2 publication Critical patent/CO6541585A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación brinda formulaciones de daptomicina en polvo novedosas que han mejorado la estabilidad química y acelerado los tiempos de reconstitución, cuando están en estado sólido. Algunos de los ejemplos de las composiciones comprenden la daptomicina y la sacarosa.
CO12097444A 2009-11-23 2012-06-08 Composiciones de lipopétidos y métodos relacionados CO6541585A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
CO6541585A2 true CO6541585A2 (es) 2012-10-16

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12097444A CO6541585A2 (es) 2009-11-23 2012-06-08 Composiciones de lipopétidos y métodos relacionados

Country Status (33)

Country Link
US (3) US8835382B2 (es)
EP (2) EP3417849A1 (es)
JP (3) JP6041673B2 (es)
CN (3) CN102712677B (es)
AR (2) AR079127A1 (es)
AU (1) AU2010321531C1 (es)
BR (1) BR112012012406B1 (es)
CA (1) CA2781666C (es)
CL (2) CL2012001336A1 (es)
CO (1) CO6541585A2 (es)
CR (1) CR20120271A (es)
CY (1) CY1120854T1 (es)
DK (1) DK2504353T4 (es)
DO (1) DOP2012000140A (es)
EC (1) ECSP12011939A (es)
ES (1) ES2686331T5 (es)
FI (1) FI2504353T4 (es)
HR (1) HRP20181380T4 (es)
HU (1) HUE039967T2 (es)
IL (1) IL219891B (es)
LT (1) LT2504353T (es)
MX (1) MX2012005993A (es)
NZ (1) NZ600118A (es)
PE (2) PE20151717A1 (es)
PL (1) PL2504353T5 (es)
PT (1) PT2504353T (es)
RS (1) RS57566B2 (es)
RU (1) RU2607526C2 (es)
SG (1) SG10201407724YA (es)
SI (1) SI2504353T2 (es)
TR (1) TR201812823T4 (es)
TW (2) TWI606838B (es)
WO (1) WO2011063419A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
MX2012005993A (es) 2009-11-23 2012-11-23 Cubist Pharm Inc Composiciones de lipopeptido y metodos relacionados.
ES2645769T3 (es) 2011-01-05 2017-12-07 Hospira, Inc. Secado por pulverización de la vancomicina
JP2014515371A (ja) * 2011-05-26 2014-06-30 キュービスト ファーマシューティカルズ， インコーポレイテッド Ｃｂ−１８３，３１５組成物および関連する方法
CN104168908A (zh) * 2012-01-12 2014-11-26 细胞基因公司 罗米地新制剂及其用途
JP2015526463A (ja) * 2012-08-23 2015-09-10 アギラ・スペシャルティーズ・プライベート・リミテッド 改善されたダプトマイシン注射用製剤
ES2552754T1 (es) 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
ES2946600T3 (es) 2016-10-21 2023-07-21 Xellia Pharmaceuticals Aps Formulaciones líquidas de daptomicina
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
MX2022010378A (es) 2020-02-28 2022-09-21 Xellia Pharmaceuticals Aps Formulacion de daptomicina.
CN115243675A (zh) 2020-03-12 2022-10-25 巴克斯特国际公司 含有山梨糖醇和甘露糖醇的组合的达托霉素制剂
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
CN1051200A (zh) 1984-10-09 1991-05-08 伊莱利利公司 制备抗菌素a-21978c复合物或因子的方法
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
NZ232763A (en) * 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (es) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
JP3421338B2 (ja) 1992-04-20 2003-06-30 アボツト・ラボラトリーズ バンコマイシンの製造方法
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
JP2003517480A (ja) 1999-12-15 2003-05-27 キュービスト ファーマシューティカルズ， インコーポレイテッド 抗菌剤としてのリポペプチド
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
BR0112393A (pt) * 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20030045484A1 (en) * 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified daptomycin
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP2005508622A (ja) 2001-08-06 2005-04-07 キュービスト ファーマシューティカルズ， インコーポレイテッド ダプトマイシン生合成遺伝子クラスターに関する組成物および方法
WO2003059964A2 (fr) 2002-01-17 2003-07-24 Atofina Polymeres supramoleculaires
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
KR20070085674A (ko) * 2005-02-14 2007-08-27 비너스 레머디스 리미티드 약제 내성균에 의한 감염 질환을 위한 비경구 병용 요법
WO2006130629A2 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP5373606B2 (ja) * 2006-07-26 2013-12-18 サンド・アクチエンゲゼルシヤフト カスポファンギン製剤
WO2008127291A2 (en) 2006-10-10 2008-10-23 Los Alamos National Security, Llc Advanced drug development and manufacturing
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
EP2170362B1 (en) 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
US20100287884A1 (en) * 2007-10-25 2010-11-18 Sangita Seshadri Powder conditioning of unit dose drug packages
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
MX2012005993A (es) 2009-11-23 2012-11-23 Cubist Pharm Inc Composiciones de lipopeptido y metodos relacionados.
HUE051133T2 (hu) 2010-11-01 2021-03-01 Melinta Subsidiary Corp Gyógyászati készítmények
CA2822447C (en) 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
US20130034597A1 (en) 2011-02-04 2013-02-07 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof

Also Published As

Publication number Publication date
JP6041673B2 (ja) 2016-12-14
PE20121517A1 (es) 2012-11-26
US9662397B2 (en) 2017-05-30
NZ600118A (en) 2014-08-29
DK2504353T4 (da) 2023-11-20
EP2504353A4 (en) 2014-04-02
AU2010321531A1 (en) 2012-06-14
CN102712677B (zh) 2015-06-03
JP2017075186A (ja) 2017-04-20
WO2011063419A2 (en) 2011-05-26
TW201703791A (zh) 2017-02-01
PL2504353T5 (pl) 2023-11-20
HRP20181380T1 (hr) 2018-10-19
ES2686331T5 (es) 2024-03-27
BR112012012406A2 (pt) 2019-12-03
AU2010321531B2 (en) 2016-11-03
SG10201407724YA (en) 2014-12-30
CY1120854T1 (el) 2019-12-11
RU2012126076A (ru) 2013-12-27
EP3417849A1 (en) 2018-12-26
BR112012012406B1 (pt) 2021-11-16
CN108785654A (zh) 2018-11-13
RS57566B1 (sr) 2018-10-31
JP6239167B2 (ja) 2017-11-29
DOP2012000140A (es) 2012-10-30
EP2504353B1 (en) 2018-07-11
AU2010321531A2 (en) 2014-10-30
TWI548414B (zh) 2016-09-11
RU2607526C2 (ru) 2017-01-10
FI2504353T4 (fi) 2023-11-30
RS57566B2 (sr) 2023-12-29
JP6088681B2 (ja) 2017-03-01
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
CN104056250A (zh) 2014-09-24
CN102712677A (zh) 2012-10-03
AR079127A1 (es) 2011-12-28
TR201812823T4 (tr) 2019-02-21
CL2012001336A1 (es) 2012-10-05
JP2013511557A (ja) 2013-04-04
SI2504353T1 (sl) 2018-10-30
AR123846A2 (es) 2023-01-18
US20140364380A1 (en) 2014-12-11
JP2016147874A (ja) 2016-08-18
US20120270772A1 (en) 2012-10-25
MX2012005993A (es) 2012-11-23
EP2504353B2 (en) 2023-09-13
SI2504353T2 (sl) 2023-11-30
ECSP12011939A (es) 2012-07-31
PL2504353T3 (pl) 2018-11-30
AU2010321531C1 (en) 2020-10-01
IL219891B (en) 2018-01-31
EP2504353A2 (en) 2012-10-03
US20160030577A1 (en) 2016-02-04
CL2015002412A1 (es) 2016-02-05
PE20151717A1 (es) 2015-11-19
CA2781666C (en) 2017-02-21
WO2011063419A3 (en) 2011-10-13
LT2504353T (lt) 2018-09-25
ES2686331T3 (es) 2018-10-17
CR20120271A (es) 2012-08-01
HRP20181380T4 (hr) 2023-11-10
DK2504353T3 (en) 2018-09-10
HUE039967T2 (hu) 2019-02-28
US8835382B2 (en) 2014-09-16
IL219891A0 (en) 2012-07-31
US9138456B2 (en) 2015-09-22
PT2504353T (pt) 2018-10-18
CA2781666A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CO6541585A2 (es) Composiciones de lipopétidos y métodos relacionados
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
UA109122C2 (uk) Синергічна гербіцидна композиція, яка містить амінопіралід і 2,4-дихлорфеноксіоцтову кислоту
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MX2013003365A (es) Composicion farmaceutica.
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
ECSP12012031A (es) Composición farmacéutica que comprende oligopéptidos
EP4403197A3 (en) Injectable formulations for organ augmentation
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
CR11772A (es) Metodos y composicion liquidas de limpieza
BR112012019997A2 (pt) composições de cuidado oral
NZ741342A (en) Daptomycin formulations and uses thereof
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
IN2012DN03404A (es)
BR112015028824A2 (pt) composição de tensoativo concentrada
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
BR112012004916A2 (pt) composições sns-595 estáveis e métodos de preparação
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
IN2015DN04074A (es)
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof